Moderna (NASDAQ: MRNA) has announced preliminary data indicating that an updated version of its SARS-CoV-2 vaccine is immunogenic against the EG.5 and FL.1.5.1 variants, recently renamed Eris and Fornax by the World Health Organization (WHO), with Eris being classified as a variant of interest (VOI). This development marks a significant milestone in the ongoing efforts to combat the evolving SARS-CoV-2 virus.
Immune Response Against Current VOIs
The company has previously demonstrated that its vaccine generates an immune response against SARS-CoV-2 XBB variants, thus completing the demonstration of immune response against all VOIs currently in circulation. This comprehensive coverage is crucial for ensuring the effectiveness of vaccines in the face of viral mutations.
Regulatory Filings and Upcoming Launch
Moderna has filed its updated booster with regulatory agencies globally and anticipates launching the vaccine by the upcoming vaccination season. The timely introduction of this updated booster is expected to enhance protection against the new variants, contributing to global health security and the ongoing fight against COVID-19.-Fineline Info & Tech
